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      Dear  Sir: 
  We would like to thank the authors for their insights. We 
agree that serologic testing performed on acute serum or cere-
brospinal fluid (CSF) specimens may not rule out a diagnosis 
of Japanese encephalitis (JE) and that we very likely under-
estimated disease burden. Although lower levels of JE virus 
(JEV) immunoglobulin (Ig) M antibodies in serum or CSF 
have been associated with poor outcome,  1   most JE patients 
develop IgM antibodies in serum within 10 days after their 
onset of illness and in CSF by 7 days after their illness onset.  2,  3  
JEV-specific IgM antibodies usually persist for at least several 
weeks. 
  In our study of 472 encephalitis patients with no evidence 
of recent JEV infection by antibody testing, 361 (77%) had 
negative JEV IgM-capture enzyme-linked immunosorbent 
assay (ELISA) testing on serum specimens collected ≥ 10 days 
after onset of illness. Of the remaining 111 JEV IgM-negative 
patients who only had a serum specimen obtained < 10 days 
after illness onset, 22 (20%) had negative JEV IgM ELISA 
testing on a CSF specimen that was collected between 7 and 
20 days after the onset of their illness. Therefore, of the 492 
patients evaluated during this study, 20 (4%) had laboratory 
evidence of recent JEV infection, and 383 (78%) had JE ruled 
out as the cause of their encephalitis. Although the remain-
ing 89 (18%) patients had negative JEV IgM testing on serum 
and/or CSF specimens, JE could not be definitively ruled out 
as the cause of their illness (i.e., JEV unknown). We chose 
to conservatively assess burden by determining the propor-
tion of individuals with positive laboratory findings over all 
individuals who had testing, regardless of the specimen tim-
ing. However, if the 89 patients who may be considered JEV 
unknown were as likely as those with optimally timed speci-
mens to have JE (20/403; 5%), approximately five additional 
JE cases could have been added to the burden calculation. 
  This is the first study to document human JEV infection 
in Bangladesh since 1977. However, because of the meth-
ods used (i.e., every fourth patient meeting the clinical case 
definition for encephalitis was selected for laboratory evalu-
ation) and limitations in case finding and laboratory testing, 
we likely captured a small proportion of JE cases occurring 
within the surveillance area during the study period, further 
contributing to a substantial underestimation of disease inci-
dence. The findings of this study indicate that JEV infection is 
a potentially important cause of vaccine-preventable encepha-
litis in Bangladesh and warrants study to further characterize 
the epidemiology of JEV infection. 
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